Page last updated: 2024-08-24

atorvastatin and Coronary Disease

atorvastatin has been researched along with Coronary Disease in 399 studies

Research

Studies (399)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	23 (5.76)	18.2507
2000's	292 (73.18)	29.6817
2010's	73 (18.30)	24.3611
2020's	11 (2.76)	2.80

Authors

Authors	Studies
Dammen, T; Fagerland, M; Husebye, E; Kristiansen, O; Munkhaugen, J; Peersen, K; Perk, J; Sverre, E; Vethe, NT	1
Carvajal-Gonzalez, S; Dullea, R; Furtado, JD; Nicholls, SJ; Ruotolo, G; Sacks, FM	1
Andersen, AM; Bergan, S; Husebye, E; Jensen, EP; Kristiansen, O; Lauritzen, T; Munkhaugen, J; Nebauer, SD; Peersen, K; Svarstad, AC; Sverre, E; Vethe, NT; Villseth, M	1
Feng, J; Li, H; Liu, T; Shen, H; Sun, L; Wang, T; Wu, J; Xu, L; Yu, L; Zhang, H	1
Bergan, S; Gjertsen, E; Gullestad, L; Husebye, E; Kristiansen, O; Munkhaugen, J; Peersen, K; Sverre, E; Vethe, NT; Weedon-Fekjaer, H	1
Parthasarathy, S; Rajathei, DM; Selvaraj, S	1
Bergan, S; Fagerland, MW; Husebye, E; Kristiansen, O; Munkhaugen, J; Vethe, NT	1
Li, J; Liu, X; Wang, G; Wang, J; Yu, H; Zhang, J; Zhu, R	1
Bergan, S; Dammen, T; Gjertsen, E; Gullestad, L; Husebye, E; Kristiansen, O; Lindberg, M; Munkhaugen, J; Otterstad, JE; Peersen, K; Perk, J; Prunés Jensen, E; Sverre, E; Vethe, NT; Wang Fagerland, M	1
Hoang, T; Kim, J	1
He, Y; Li, PB; Lin, QW; Liu, H; Su, WW; Wang, YG; Wu, H; Yan, ZH; Yao, HL; Zhang, WJ	1
Chen, L; Geng, H; Li, K; Liu, MM; Luo, W; Ma, J; Yang, X	1
Bowman, L; Braunwald, E; Cannon, CP; Chen, F; Collins, R; Hopewell, JC; Landray, MJ; Sammons, E; Stevens, W; Valdes- Marquez, E; Wallendszus, K; Wiviott, S	1
Ansheles, AA; Rvacheva, AV; Sergienko, IV	1
Athyros, VG; Katsiki, N; Mikhailidis, DP	1
Jannowitz, C; Laufs, U; Pittrow, D	1
Mikhailidis, DP; Paraskevas, KI	1
Fernando, T; Kang, Q; Li, X; Wan, Z; Yang, M	1
Anil, C; Bozkus, Y; Demir, C; Kut, A; Mousa, U; Nar, A; Tutuncu, NB	1
Ballantyne, CM; Baum, SJ; Davidson, MH; Koren, A; Langslet, G; Mandel, J; McCullough, PA; Sanganalmath, SK; Shah, PK	1
Barter, P; Boekholdt, SM; Fayyad, R; Hovingh, GK; Kastelein, JJ; Melamed, S; Ray, KK; Vallejo-Vaz, AJ; Waters, DD	1
Song, L; Wang, X; Zou, G	1
Cai, Y; Chen, C; Hu, Z; Li, C; Liu, X; Liu, Y; Luo, H; Wang, DZ; Wu, G; Xia, X; Xu, Z; Yang, Y; Yu, J; Zeng, C; Zhang, W; Zhang, X	1
Bagheri, J; Davarpasand, T; Forouzannia, SK; Gorabi, AM; Jalali, A; Lotfi-Tokaldany, M; Shekari, A; Talasaz, AH	1
Hradec, J; Sutradhar, S; Zamorano, J	1
Li, Y; Liu, J; Liu, X; Lv, Q; Ma, C; Qi, Y; Sun, J; Wang, M; Wang, W; Zhao, D	1
Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH	1
Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Laskey, R; Olsson, AG; Pedersen, TR; Tikkanen, MJ; Wun, CC	1
Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E	1
Bangalore, S; Deedwania, P; Demicco, DA; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH	1
He, BX; Qiu, J; Shi, L; Zeng, XH; Zhao, SJ	1
Abad, L; Dueñas-Laita, A; Gonzalez-Sagredo, M; Pérez-Castrillón, JL; Riancho, JA; Ruiz-Mambrilla, M; Vega, G; Zarrabeitia, MT	1
Kapoor, A; Kumar, S; Rai, H; Sinha, N; Tewari, S	1
Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Ovbiagele, B; Sillesen, H; Welch, KM; Zivin, J	1
Amarenco, P; Arsenault, BJ; Bao, W; Barter, P; Boekholdt, SM; DeMicco, DA; Mora, S; Pedersen, T; Tardif, JC; Waters, DD	1
Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM	1
Guo, X; Huang, X; Wang, Q	1
Ambegaonkar, B; Davies, G; Ejzykowicz, F; Hsu, TY; Laires, PA	1
Arsenault, BJ; Bao, W; Byun, YS; DeMicco, D; Laskey, R; Lee, JH; Tsimikas, S; Witztum, JL; Yang, X	1
Kritharides, L; Nicholls, SJ	1
Adamova, IY; Afanasieva, OI; Balakhonova, TV; Ezhov, MV; Konovalov, GA; Pogorelova, OA; Pokrovsky, SN; Safarova, MS; Tripoten, MI	1
Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM	1
Hua, L; Li, Y; Liu, H; Wang, D; Xiong, X; Zhao, H	1
Deedwania, PC; Fayyad, RS; Laskey, RE; Stone, PH; Wilson, DJ	1
Eckard, AR; Longenecker, CT; McComsey, GA	1
Einecke, D	2
Stiefelhagen, P	1
Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y	1
Yamagishi, S	1
Akcay, B; Doven, O; Erol, T; Gen, R; Kocum, TH; Ozcan, TI; Tekin, A	1
Kevelaitiene, S; Slapikas, R	1
Chan, KC; Chou, HH; Chou, MC; Huang, CN	1
Badyal, DK; Chopra, S; Gupta, A; Jaison, TM; Khosla, PP; Uppal, B	1
Bybee, KA; Lavie, CJ; O'Keefe, JH	1
Bittner, VA; Breazna, A; Carmena, R; Deedwania, PC; Dobson, S; Kastelein, JP; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, AL	1
Acharjee, S; Welty, FK	1
Ballantyne, CM; Cain, VA; Raichlen, JS	1
Amarenco, P; Breazna, A; Callahan, A; Chaturvedi, S; Goldstein, LB; Hennerici, M; Rudolph, A; Sillesen, H; Welch, MA; Zivin, J	1
Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Zivin, J	1
Zuber, M	1
Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P	1
Barbik-Zhagar, B; Belenkov, IuN; Mareev, VIu; Oganov, RG	1
Braunwald, E; Cairns, R; Cannon, CP; Morrow, DA; Ray, KK; Ridker, PM	1
Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E; Veglia, F	1
Davidson, MH; Fayyad, RS; Koren, MJ; Reed, DP; Wilson, DJ; Zuckerman, A	1
Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ	1
Corson, MA	1
Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H	1
Coull, BM; Johnston, SC	1
Dahlof, B; Poulter, NR; Sever, PS; Wedel, H	1
Braga, MF; Gupta, M; Teoh, H; Tsigoulis, M; Verma, S	1
Karadağ, B; Ongen, Z; Yilmaz, Y	1
Welch, KM	1
Deedwania, P; Singh, V	1
Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Kashima, Y; Koshikawa, M; Koyama, J; Kumazaki, S; Tomita, T; Tsutsui, H	1
Ak, K; Arsan, S; Eksioglu-Demiralp, E; Iqbal, O; Isbir, S; Tetik, S; Yardimci, T	1
Deng, JT; Hu, XY; Li, L; Liu, XL; Shang, YY; Wang, ZH; Zhang, LP; Zhang, W; Zhang, Y; Zhong, M	1
Ege, E; Kurban, S; Mehmetoglu, I	1
Abate, N; Ballantyne, CM; Catapano, AL; Davidson, MH; Polis, AB; Smugar, SS; Tershakovec, AM	1
Cox, DR; Hinds, DA; Hovingh, GK; Hyde, CL; Kastelein, JJ; Paciga, SA; Thompson, JF; Wood, LS	1
Arishiro, K; Hanafusa, T; Hoshiga, M; Ishihara, T; Kohbayashi, E; Miyazaki, N; Nakakoji, T; Negoro, N; Okabe, T	1
Cater, NB; Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ	1
Breazna, A; Deedwania, PC; DeMicco, DA; Greten, H; LaRosa, JC; Shepherd, J; Wenger, NK	1
Amarenco, P; Benavente, O; Callahan, A; Goldstein, LB; Hennerici, MG; Sillesen, H; Welch, KM; Zivin, JA; Zweifler, RM	1
Ben-Yehuda, O; Bird, S; Constance, C; Hanson, ME; Jones-Burton, C; Lee, R; Tershakovec, AM; Wenger, NK; Zieve, F	1
Cao, HY; Li, J; Li, ZQ; Pan, W; Sun, YM; Wang, LF	1
Eckel, RH	1
Buxton, M; Dahlöf, B; Eriksson, J; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H	1
Mombelli, G; Sirtori, CR	1
Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Tershakovec, AM	1
Bangalore, S; DeMicco, D; Kostis, JB; LaRosa, JC; Messerli, FH; Wun, CC; Zuckerman, AL	1
Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F	1
Benowitz, NL; Breazna, A; DeMicco, DA; Frey, P; Pipe, A; Samuels, L; Waters, DD; Wun, CC	1
Arsenault, BJ; Bao, W; Barter, P; Deedwania, P; DeMicco, DA; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Preston, GM; Shepherd, J; Waters, DD; Wenger, NK	1
Blankier, S; Ito, S; McCrindle, BW; Yeung, RS	1
Asuphol, O; Chaiyakunapruk, N; Dhippayom, T; Jeanpeerapong, N; Poowaruttanawiwit, P	1
Takagi, H; Umemoto, T	1
Djoussé, L; Gaziano, JM; Rahilly-Tierney, C; Sesso, HD	1
John, H; Kitas, GD; Toms, TE	1
Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA	1
Boh, M; Ceska, R; Jezovnik, M; Opolski, G; Poredos, P	1
Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P	1
Chang, CL; Gupta, AK; Poulter, NR; Sever, PS; Whitehouse, A	1
Braunwald, E	2
Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D	1
Schalkwijk, CG; Simsek, S; Wolffenbuttel, BH	1
McKenney, JM	1
Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M	1
Hitman, GA	1
Arsenault, BJ; Bao, W; Barter, PJ; Boekholdt, SM; Davaine, JM; DeMicco, DA; Huijgen, R; Kastelein, JJ; Lambert, G; Petrides, F; Rye, KA; Tabet, F	1
Chen, X; Feng, LX; Ge, CJ; Huo, Y; Lü, SZ; Meng, K; Song, XT; Yuan, F	1
Bittner, V; DeMicco, DA; LaRosa, JC; Messig, M; Waters, DD; Wenger, NK	1
Christensen, JH; Lundbye-Christensen, S; Lysgaard, C; Nielsen, MS; Riahi, S; Schmidt, EB	1
Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD	1
Artamoshina, NE; Belaya, OL; Bondar, KY; Kuropteva, ZV; Lazutina, OM; Raider, LM; Yakovleva, TV	1
Berra, C; Branchi, A; Colombo, E; Dalla Valle, E; Fiorenza, AM; Muzio, F; Rovellini, A; Sommariva, D; Torri, A	1
Mikhailidis, DP; Wierzbicki, AS	2
Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Papageorgiou, AA; Symeonidis, AN	1
Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ	2
Supanich, B	1
Daly, JA; Ferrari, A; Gleason, JA; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T	1
Ceska, R; Fialova, L; Malbohan, I; Stulc, T; Zima, T	1
Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Mikhailidis, DP; Papageorgiou, AA; Symeonidis, AN	1
Farmer, JA	1
Laucevicius, A; Simaitis, A	1
Gylling, H; Lindbohm, N; Miettinen, TA; Miettinen, TE; Rajaratnam, RA; Relas, H	1
Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA	1
Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J	2
Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ	1
Clark, LT	1
Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H	2
Khan, BV; Khan, QA; Lauten, WB; Lerakis, S; Parthasarathy, S; Rahman, ST; Rajagopalan, S	1
Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL	1
Akbulut, H; Akbulut, M; Arslan, N; Ilkay, E; Karaca, I; Pekdemir, M; Yavuzkir, M	1
Sudhop, T; von Bergmann, K	1
Hedner, T; Himmelman, A; Kjeldsen, SE	1
Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H	1
Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA	1
Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Slavina, NN; Vaulin, NA	1
Kerrigan, AT	1
Chan, D; Dane-Stewart, CA; Hung, J; Mamo, JC; Pal, S; Thompson, P; Watts, GF	1
Després, JP; Lemieux, I; Salomon, H	1
Karas, RH; Kimmelstiel, C; Pourati, I; Rand, W	1
Li, QZ; Nie, S; Xu, ZM; Zhao, SP; Zhou, HN	1
Isomustajärvi, M; Laakso, J; Laaksonen, R; Lakka, TA; Lehtimäki, T; Päivä, H; Ruokonen, I; Salonen, JT; Valkonen, VP	1
Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T	1
Fathi, R; Haluska, B; Isbel, N; Johnson, D; Marwick, TH; Short, L	1
Guyton, JR; Herrington, DM; McGowan, MP; Shear, C; Waters, DD; Wenger, NK	1
Kjeldsen, S; Midtbø, K; Svilaas, A; Syvertsen, JO; Westheim, A	1
Błaszczyk, J; Cegliński, T; Grycewicz, J; Irzmański, R; Kowalczyk, E; Kowalski, J; Pawlicki, L	1
März, W	2
Saw, J; Topol, EJ	1
Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD	1
Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Milionis, HJ; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN	1
Li, J; Xu, Z; Ye, H; Zhao, S; Zhou, H	1
Tellier, P	1
Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C	1
Daida, H; Miyauchi, K; Shimada, K	1
Kulbertus, H; Scheen, AJ	1
McKerracher, A	1
Jackson, G	2
Athyros, VG; Bouloukos, VI; Elisaf, M; Mercouris, BR; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, A; Symeonidis, AN	1
Mason, P	1
Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN	1
Gürel, CV; Güzelsoy, D; Kaya, A; Tekin, A; Tekin, G; Ulutin, T; Yiğit, Z	1
Ceyhan, C; Ercan, E; Onbasili, AO; Tekten, T; Turkoglu, C	1
Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Mackness, MI; Neil, HA; Thomason, MJ	1
Hegmann, T	1
Auer, J; Eber, B; Weber, T	1
Daida, H; Kurata, T; Miyauchi, K; Okazaki, S; Sato, H; Shimada, K; Yokoyama, T	1
Traut, V	1
Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Palmer, G; Pedersen, TR; Tikkanen, MJ	1
Athyros, VG; Bouloukos, VI; Daskalopoulou, SS; Kakafika, AI; Langer, A; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN	1
McGowan, MP	1
Hunninghake, DB; Koren, MJ	1
Cannon, CP; Ray, KK	1
Deedwania, PC	1
Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM	1
Feely, J; Sigurdsson, EL; Strandberg, TE	1
Downey, J; Jones, PH; Karalis, DG; McKenney, JM	1
Bellia, A; Carnevale, R; Ferro, D; Lauro, R; Lenti, L; Pignatelli, P; Sanguigni, V; Sorge, R; Tesauro, M; Violi, F	1
Griebenow, R	1
Cheng, TO	1
Pitt, B	1
Barter, P; Fruchart, JC; Gotto, AM; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Shear, C; Shepherd, J; Waters, DD; Wenger, NK	1
Bartok, A; Huber, K; Jetzl, A; Kopp, CW; Minar, E; Seidinger, D; Stefenelli, T; Steiner, S	1
Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C	1
Schwartz, GG	1
Badaracco, R; Brizuela, M; Cialzeta, JR; Doval, H; Farías, EF; Franciosi, V; Macin, SM; Medina, F; Perna, ER; Tajer, C	1
Curtiss, FR	1
de Graaf, J; Stalenhoef, AF; van Tits, LJ	1
Adgey, J; Allen, C; Bedarida, GV; Cruz-Fernández, JM; Johnson-Levonas, AO; Massaad, R	1
McFarlane, SI; Murad, O; Palmer, J; Sowers, J	1
Scheen, AJ	2
Jarernsiripornkul, N; Kiatchusakul, S; Ojongpian, S; Srinakarin, J; Tantikosoom, W; Thinkhamrop, B	1
Auer, J; Eber, B; Lamm, G	1
Southern, W	1
Braunwald, E; Cannon, CP; Murphy, SA	1
Ravnskov, U; Rosch, PJ; Sutter, MC	1
Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Tselepis, AD	1
Climent, VE; de Teresa, L; García-Herola, A; Lorenzo, S; Marín, F; Roldán, V; Sogorb, F; Tello, A	1
Albertini, JP; Charniot, JC; Hantz, E; Le Moyec, L; Valensi, P	1
Bays, H; Davidson, M; McKenney, J	1
Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O	1
Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M	1
Amyot, R; Arnold, M; Bonafede, N; Cannon, CP; Dupuis, J; Lonn, E; Ricci, J; Rouleau, JL; Roux, R; Tardif, JC; Title, LM; Woo, A	1
Hobbs, FD	1
Amanavicius, N; Christensen, JH; Christoffersen, RP; Jensen, HS; Karmisholt, J; Niebuhr, U; Riahi, S; Schmidt, EB; Toft, E	1
Davidson, MH	2
Potaczek, DP; Szczeklik, A; Undas, A	1
Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K	1
Bots, AF; Kastelein, JJ	1
Koren, MJ	1
Avcu, F; Ural, AU	1
Ballantyne, CM; Brady, WE; Davies, MJ; Feldman, TA; McKenney, J; Mitchel, YB; Palmisano, J; Shah, A	1
Clearfield, M	2
Qi, SS; Shen, XQ; Zeng, GF; Zhou, HN; Zhou, SH; Zhou, T	1
Dincer, I; Erol, C; Ertas, F; Ongun, A; Ozdol, C; Turhan, S	1
Lynch, T	1
Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS	1
Antoniades, C; Stefanadis, C; Tousoulis, D	1
Lesaffre, E; Rizopoulos, D; Tsonaka, R	1
Ballantyne, CM; Bertolami, M; Cain, VA; Hernandez Garcia, HR; Nul, D; Raichlen, JS; Stein, EA; Theroux, P; Weiss, R	1
Chetty, N; Munster, M; Naran, NH	1
Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC	1
Barter, P; Breazna, A; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, S; Haffner, S; Hsia, J; LaRosa, J; Shepherd, J; Waters, D	1
Braunwald, E; Cannon, CP; Jarolim, P; McCabe, CH; Morrow, DA; Ray, KK; Sabatine, MS; Scirica, BM; Shui, A	1
Plans-Rubió, P	1
Asai, K; Ito, T; Kosaka, T; Kuhara, Y; Kuroda, Y; Ozaki, Y; Shinjo, H; Takashima, H; Wakita, Y; Waseda, K; Yasukawa, T	1
Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE	1
Bolaman, Z; Kadikoylu, G; Ozgel, N; Yenisey, C	1
Barter, P; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, SM; Haffner, S; Kastelein, JJ; LaRosa, JC; Schachner, H; Shepherd, J; Waters, DD	1
Athyros, VG; Elisaf, M; Ganotakis, ES; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Papageorgiou, AA; Tziomalos, K	1
Chello, M; Colonna, D; Covino, E; D'Ambrosio, A; Di Sciascio, G; Miglionico, M; Nusca, A; Pasceri, V; Patti, G	1
Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA	1
Gazi, IF; Mikhailidis, DP	1
Alemao, E; Jousilahti, P; Salomaa, V; Sintonen, H; Yin, D	1
Barter, P; Breazna, A; Carter, R; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Waters, DD	1
Banach, M; Barylski, M; Grycewicz, J; Irzmański, R; Kowalski, J; Pawlicki, L	1
Barron, TI; Bennett, K; Feely, J	1
Elkind, MS	1
Alhan, CC; Avkaroğullari, M; Cayli, M; Demir, M; Demirtaş, M; Dönmez, Y; Inal, T; Kanadaşi, M; Koç, M; San, M; Usal, A	1
Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP	1
Aukrust, P; Boullier, A; Breland, U; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Hansson, GK; Kjekshus, J; Ovchinnikova, O; Quehenberger, O; Robertson, AK; Sandberg, WJ; Smith, C; Taskén, K; Waehre, T; Yndestad, A; Øie, E	1
Chyrchel, M; Dubiel, JS; Dudek, D; Dziewierz, A; Legutko, J; Rakowski, T; Rzeszutko, L	1
Goldstein, MR	2
Mascitelli, L; Pezzetta, F	1
Bernardi, M; Caputo, F	1
Butler, R; Wainwright, J	1
Nesto, RW; Singh, PP	1
Bairey Merz, CN; Cosin-Aguilar, J; Deedwania, P; Koylan, N; Luo, D; Ouyang, P; Piotrowicz, R; Schenck-Gustafsson, K; Sellier, P; Stein, JH; Stone, PH; Thompson, PL; Tzivoni, D	1
Gotto, AM	1
Alber, HF; Dichtl, W; Dörler, J; Frick, M; Pachinger, O; Stocker, EM; Süssenbacher, A; Weidinger, F	1
Chan, IH; Chan, W; Cheng, KK; Fung, JW; Kong, SL; Lam, CW; Lam, L; Lee, SW; Lin, H; Sanderson, JE; Yu, CM; Zhang, Q	1
Choudhry, NK; Levin, R; Winkelmayer, WC	1
Bal, BS; Kant, R; Mahajan, M; Sharma, R; Singh, B	1
Colonna, G; Di Sciascio, G; Fischetti, D; Miglionico, M; Montinaro, A; Pasceri, V; Patti, G; Sardella, G	1
Blagden, MD; Chipperfield, R	1
Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S	1
Gandhi, SK; Ghali, JK; Hassman, DR; Insull, W; Miller, E; Y As, JW	1
Deedwania, PC; Gold, A; Gupta, M; Stein, M; Ycas, J	1
Botteman, MF; Damen, J; Koren, MJ; Kuntze, CE; Liu, LZ; Mamdani, M; Straka, RJ	1
Kulbertus, H	1
Bittner, V; Herrington, DM; Lewis, SJ; Welty, FK; Wenger, NK	2
Claeys, M; Commers, K; Deforce, J; Ducobu, J; Nachtergaele, H; Van Mieghem, W; Vandenbroucke, M	1
Andrade, LE; Ferreira, GA; Navarro, TP; Sato, EI; Telles, RW	1
Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Pirpasopoulou, A; Skaperdas, A; Tziomalos, K	1
Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC	1
Barter, P; Bittner, V; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Maroni, J; Szarek, M	1
Arca, M; Gaspardone, A	2
Arca, M	1
Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E	1
Bittner, V; Breazna, A; Deedwania, P; Dobson, S; Kastelein, JJ; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, A	1
Campese, VM; Park, J	1
Barter, PJ; Brewer, B; Buhr, KA; Caulfield, M; Eriksson, M; Fisher, MR; Grundy, SM; Kastelein, JJ; Komajda, M; Lopez-Sendon, J; Mosca, L; Revkin, JH; Shear, CL; Tall, AR; Tardif, JC; Waters, DD	1
Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R	1
Armani, A; Toth, PP	1
Azuma, A; Matsubara, H; Sasaki, S; Sawada, T; Yamada, T	1
Cannon, CP; Kumar, A	1
Lyseng-Williamson, KA; Plosker, GL	1
Baskurt, M; Cakar, MA; Coskun, U; Guzelsoy, D; Okcun, B; Yildiz, A	1
Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H	1
Bestehorn, HP; Büttner, HJ; Frundi, D; Hochholzer, W; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM	1
Braunwald, E; Cannon, CP; Catanese, JJ; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Ranade, K; Rowland, CM; Sabatine, MS; Simonsen, KL; Tong, CH	1
Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK	1
Mascitelli, L; Vos, E	1
Alter, RA	1
Arsova, V; Jurukovska-Nospal, M; Levchanska, J; Sidovska-Ivanovska, B	1
Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B	1
Gawaz, M; Geisler, T; Paterok, M; Zürn, CS	1
Anagnostis, P; Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, C; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Paraskevas, KI; Tziomalos, K	1
Asmar, R; Duffield, E; Faergeman, O; Hill, L; Sosef, F; Wiklund, O; Windler, E	1
Breazna, A; Deedwania, PC; Kostis, JB; LaRosa, JC	1
Gratsianskii, NA; Vaulin, NA	1
Hallinen, T; Martikainen, J; Niskanen, L; Peura, P; Soini, E	1
Gao, CY; Li, MW; Liang, ZT; Liao, YH; Wang, XP; Zeng, QT	1
Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR	1
Black, DM; Brown, WV; McCormick, LS; Pitt, B; Waters, D	1
Ghali, JK	1
Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A	1
Assmann, G; Funke, H; Schulte, H; von Eckardstein, A	1
Olsson, AG	1
Abdallah, P; Bakker-Arkema, RG; Black, DM; Drehobl, M; Early, JL; Hunninghake, D; McBride, S; Schrott, H; Wigand, JP	1
D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW	1
Lee, TH	1
Strandberg, TE; Tikkanen, MJ; Vanhanen, H	1
Geiss, HC; Parhofer, KG; Schwandt, P	1
Ewy, GA	1
Brown, WV; Eisenberg, D; McCormick, LS; Pitt, B; Schwartz, L; Shurzinske, L; Title, LM; van Boven, AJ; Waters, D	1
Klein, G; März, W; Neiss, A; Wehling, M; Wollschläger, H	1
Gänzer, H; Kirchmair, R; Patsch, JR; Sturm, W	1
Baim, DS; Carrozza, JP; Cohen, DJ	1
Davidson, CJ; Ricciardi, MJ	1
Bloom, JM	1
Eminton, Z; Fowler, G; Maton, S; Neil, HA; Patel, H	1
Waters, DD	1
Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I	1
Auch-Schwelk, W; Elsner, M; Mach, S; Schächinger, V; Walter, DH; Zeiher, AM	1
Waters, D	2
Puri, S; Saucedo, J; Singh, BM; Talley, JD	1
Darioli, R; Keller, U; Mordasini, R; Noseda, G; Riesen, W; Schaffhauser, B; Shokry, A	1
O'Neill, BJ	1
Black, DM; Davidson, MH; Hunninghake, D; Isaacsohn, JL; McLain, R; Singer, R	1
Eisenberg, D	1
Blumenthal, RS; Cohn, G; Schulman, SP	1
Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC	1
Armitage, J; Betteridge, DJ; Colhoun, H	1
Maron, DJ	1
Park, A	1
Dzurick, J; Hiller, D; Peralta, B; Rindone, JP	1
Campeau, L	1
Crouch, MA	1
Marschall, HU	1
Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; O'Malley, PG; Taylor, AJ	1
Rosenson, RS; Schaefer, EJ; Tangney, CC	1
Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW	1
Allen, SE; Attanasio, E; Russo, P	1
Hilleman, DE; Lenz, TL; Wurdeman, RL	1
Wierzbicki, AS	1
Mokuno, H	1
Kajinami, K; Takekoshi, N	1
Brohet, C; De Backer, G; Heller, F; Muls, E	1
Maclaine, GD; Patel, H	1
Adler, K; Aicher, A; Dimmeler, S; Fichtlscherer, S; Martin, H; Vasa, M; Zeiher, AM	1
Mikhaildis, DP; Reynolds, TM; Wierzbicki, AS	1
Ito, MK	1
Breuer, HW	1
Beckmann, S; Bocksch, W; Gross, M; Hausmann, D; Karsch, KR; Koschyk, DH; Kreuzer, J; Schartl, M; Voelker, W	1
Athyros, VG; Bouloukos, VJ; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN	1
Mikhaildis, DP; Reynolds, TR; Wierzbicki, AS	1
Chaitman, BR; Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Schwartz, GG; Waters, D; Zeiher, A	1
Anthony, M; Bleske, BE; Casselberry, N; Datwani, M; Secontine, SG; Shea, MJ; Uhley, VE; Willis, RA	1
Susekov, AV	1
Auer, J; Eber, B	1
Arad, Y; Guerci, AD; Newstein, D; Roth, M	1
Ahotupa, M; Kantola, I; Nieminen, MS; Strandberg, T; Vanhanen, H; Vasankari, T; Viikari, J	1
Hsue, PY; Waters, DD	1
Ellis, PM	1
Karalis, DG; Ross, AM; Scott, R; Vacari, RM; Zarren, H	1
Stein, EA	1
Arnesen, H; Hjermann, I; Seljeflot, I; Tonstad, S	2
Brödl, UC; Empen, K; Otto, C; Parhofer, KG	1
Engler, H; Korte, W; Noseda, G; Riesen, WF; Risch, M	1
Delaval, D; Després, JP; Lemieux, I; Salomon, H	1
Barsotti, A; Brunelli, C; Ghigliotti, G; Leslie, S; Olivotti, L; Rossettin, P; Spallarossa, P	1
Gavish, D; Harats, D; Leibovitz, E	1
Acevedo, M; Francis, G; Lauer, MS; Sprecher, DL	1
Alber, HF; Dichtl, W; Dulak, J; Frick, M; Pachinger, O; Schwarzacher, SP; Weidinger, F	1

Reviews

50 review(s) available for atorvastatin and Coronary Disease

Article	Year
Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants. Nutrients, 2020, Jul-25, Volume: 12, Issue:8 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome	2020
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies. Internal medicine journal, 2014, Volume: 44, Issue:6 Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL	2014
Statins to improve cardiovascular outcomes in treated HIV infection. Current opinion in infectious diseases, 2016, Volume: 29, Issue:1 Topics: Atorvastatin; Carotid Intima-Media Thickness; Coronary Disease; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Precision Medicine; Primary Prevention; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Treatment Outcome; United States	2016
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. Atherosclerosis, 2016, Volume: 254 Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2016
[A new approach to the treatment of dyslipidemia]. Medicina (Kaunas, Lithuania), 2008, Volume: 44, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors	2008
Atorvastatin and cardiovascular risk in the elderly--patient considerations. Clinical interventions in aging, 2008, Volume: 3, Issue:2 Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic	2008
[Atorvastatin in secondary prevention]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37 Suppl 2 Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Secondary Prevention; Stroke	2009
Review of the SPARCL trial and its subanalyses. Current atherosclerosis reports, 2009, Volume: 11, Issue:4 Topics: Age Factors; Atorvastatin; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrroles; Risk Factors; Sex Factors; Stroke	2009
Reducing morbidity and mortality in high risk patients with statins. Vascular health and risk management, 2009, Volume: 5, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Kidney Failure, Chronic; Metabolic Diseases; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors	2009
Rheumatoid arthritis: is it a coronary heart disease equivalent? Current opinion in cardiology, 2011, Volume: 26, Issue:4 Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Risk Factors	2011
Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. Postgraduate medicine, 2012, Volume: 124, Issue:1 Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Flushing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Medication Adherence; Niacin; Pyrroles	2012
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Treating dyslipidemia with statins: the risk-benefit profile. American heart journal, 2003, Volume: 145, Issue:3 Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States	2003
[LDL cholesterol in normal range. The lower the better? Implications of the GREACE study]. MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Placebos; Pravastatin; Pyrroles; Risk Factors; Simvastatin	2003
[Ezetimibe: from pharmacology to clinical trials]. Annales d'endocrinologie, 2003, Volume: 64, Issue:6 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome	2003
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Current opinion in lipidology, 2004, Volume: 15, Issue:6 Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes	2004
Statins and CVD prevention in the diabetic population: implications of the CARDS trial. Current diabetes reports, 2005, Volume: 5, Issue:3 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis	2005
["Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease]. Revue medicale de Liege, 2005, Volume: 60, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic	2005
Torcetrapib/atorvastatin combination therapy. Expert review of cardiovascular therapy, 2005, Volume: 3, Issue:5 Topics: Animals; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines	2005
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. International journal of cardiology, 2006, Jun-16, Volume: 110, Issue:2 Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Models, Biological; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides	2006
Reducing residual risk for patients on statin therapy: the potential role of combination therapy. The American journal of cardiology, 2005, Nov-07, Volume: 96, Issue:9A Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Risk Factors	2005
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology, 2006, Jun-06, Volume: 47, Issue:11 Topics: Acute Disease; Atorvastatin; Cardiac Output, Low; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Natriuretic Peptide, Brain; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome	2006
Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs, 2007, Volume: 67 Suppl 1 Topics: Angioplasty, Balloon; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Myocardial Ischemia; Pyrroles	2007
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs, 2007, Volume: 67 Suppl 1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke	2007
Atorvastatin: its clinical role in cerebrovascular prevention. Drugs, 2007, Volume: 67 Suppl 1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Stroke	2007
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. Journal of interventional cardiology, 2007, Volume: 20, Issue:6 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional	2007
Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events. PharmacoEconomics, 2007, Volume: 25, Issue:12 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors	2007
Statins revisited. Harvard heart letter : from Harvard Medical School, 1998, Volume: 8, Issue:9 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Naphthalenes; Pyrroles	1998
Maximizing the cost-effectiveness of lipid-lowering therapy. Archives of internal medicine, 1998, Oct-12, Volume: 158, Issue:18 Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin	1998
Addressing the challenge. European heart journal, 1998, Volume: 19 Suppl M Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pyrroles	1998
[Statins in diabetic hyperlipidemia]. Wiener medizinische Wochenschrift (1946), 1999, Volume: 149, Issue:5-6 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles; Risk Factors; Triglycerides	1999
Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. European heart journal, 2000, Volume: 21, Issue:13 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Myocardial Revascularization; Pyrroles	2000
HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Current medical research and opinion, 2000, Volume: 16, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles; Simvastatin	2000
Clinical data: AVERT and QUO VADIS. The Canadian journal of cardiology, 2000, Volume: 16 Suppl E Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Coronary Angiography; Coronary Disease; Decision Making; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoquinolines; Myocardial Revascularization; Pyrroles; Quinapril; Randomized Controlled Trials as Topic; Tetrahydroisoquinolines; Treatment Outcome	2000
Implications of the atorvastatin versus revascularization treatment (AVERT) study for the clinician. Current cardiology reports, 2000, Volume: 2, Issue:5 Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Treatment Outcome	2000
Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. Journal of the American College of Cardiology, 2000, Volume: 36, Issue:3 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Myocardial Ischemia; Myocardial Revascularization; Pyrroles; Randomized Controlled Trials as Topic	2000
Percutaneous coronary intervention versus medical therapy for coronary heart disease. Current atherosclerosis reports, 2000, Volume: 2, Issue:4 Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Nitrates; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome	2000
Statin trials in progress: unanswered questions. Current atherosclerosis reports, 2001, Volume: 3, Issue:1 Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin	2001
Lipid lowering and coronary bypass graft surgery. Current opinion in cardiology, 2000, Volume: 15, Issue:6 Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Postoperative Period; Pyrroles; Randomized Controlled Trials as Topic	2000
Effective use of statins to prevent coronary heart disease. American family physician, 2001, Jan-15, Volume: 63, Issue:2 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin	2001
Statin therapy--what now? Drug and therapeutics bulletin, 2001, Volume: 39, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome	2001
Atorvastatin. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:5 Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles	2001
[AVERT [The Atorvastatin versus Revascularization Treatment]]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic	2001
[Atorvastatin]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic	2001
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Current medical research and opinion, 2001, Volume: 17, Issue:1 Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Pyridines; Pyrroles; Risk Factors; Triglycerides	2001
[Substantiation of increasing doses of statins in clinical practice]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:4 Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors	2001
A clinical focus on statins. Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:3 Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin	2001
Managing dyslipidemia in the high-risk patient. The American journal of cardiology, 2002, Mar-07, Volume: 89, Issue:5A Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States	2002

Trials

179 trial(s) available for atorvastatin and Coronary Disease

Article	Year
Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC cardiovascular disorders, 2021, 12-16, Volume: 21, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Cross-Sectional Studies; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Norway; Prevalence; Risk Factors; Treatment Outcome	2021
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. Arteriosclerosis, thrombosis, and vascular biology, 2022, Volume: 42, Issue:2 Topics: Aged; Anticholesteremic Agents; Apolipoprotein C-III; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Coronary Disease; Ezetimibe; Female; Heart Disease Risk Factors; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged	2022
Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms. Clinical pharmacology and therapeutics, 2023, Volume: 113, Issue:4 Topics: Atorvastatin; Biomarkers; Coronary Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscle, Skeletal	2023
Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease. Pharmacology research & perspectives, 2023, Volume: 11, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Triglycerides	2023
Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease. Current drug metabolism, 2020, Volume: 21, Issue:10 Topics: Aged; Atorvastatin; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Factors; Rosuvastatin Calcium; Transcriptome	2020
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. European heart journal. Cardiovascular pharmacotherapy, 2021, 11-03, Volume: 7, Issue:6 Topics: Atorvastatin; Coronary Disease; Cross-Over Studies; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscles	2021
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, a American heart journal, 2017, Volume: 187 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Male; Middle Aged; Oxazolidinones; Research Design	2017
Effect of Atorvastatin Therapy on the Level of CD34 Bulletin of experimental biology and medicine, 2017, Volume: 163, Issue:1 Topics: AC133 Antigen; Adult; Antigens, CD34; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Coronary Disease; Endothelial Progenitor Cells; Female; Flow Cytometry; Healthy Volunteers; Humans; Male; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult	2017
Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2018, Volume: 27, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Life Style; Lipids; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium; Thyroid Function Tests; Thyroid Gland; Thyroid Nodule	2018
Effect of doxycycline and atorvastatin on improving exercise tolerance in patients with angina pectoris. Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:4(Special) Topics: Angina Pectoris; Anti-Bacterial Agents; Atorvastatin; Coronary Disease; Double-Blind Method; Doxycycline; Exercise Tolerance; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged	2018
Comparison of the effect of 80 vs 40 mg atorvastatin in patients with isolated coronary artery bypass graft surgery: A randomized clinical trial. Journal of cardiac surgery, 2019, Volume: 34, Issue:8 Topics: Aged; Atorvastatin; Biomarkers; Cardiomyopathies; Coronary Artery Bypass; Coronary Disease; Creatine Kinase, MB Form; Female; Humans; Male; Middle Aged; Postoperative Complications; Single-Blind Method; Time Factors; Troponin T	2019
Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Current medical research and opinion, 2013, Volume: 29, Issue:6 Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors	2013
Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. Journal of lipid research, 2013, Volume: 54, Issue:11 Topics: Absorption; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk	2013
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial. European heart journal, 2014, Jul-14, Volume: 35, Issue:27 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome	2014
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. International journal of cardiology, 2013, Oct-09, Volume: 168, Issue:4 Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Single-Blind Method; Treatment Outcome	2013
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. The American journal of medicine, 2014, Volume: 127, Issue:1 Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Prevalence; Pyrroles; Risk Factors; Treatment Outcome	2014
The effect of CYP3A41G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease. Journal of clinical pharmacology, 2014, Volume: 54, Issue:4* Topics: Alleles; Asian People; Atorvastatin; Coronary Disease; Cytochrome P-450 CYP3A; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles	2014
Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians. The Indian journal of medical research, 2013, Volume: 138, Issue:6 Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; India; Lipids; Male; Middle Aged; Niacin; Pyrroles; Risk Factors	2013
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Prognosis; Pyrroles; Risk Assessment; Stroke; Treatment Outcome; Vascular Diseases	2014
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). The American journal of cardiology, 2014, Apr-15, Volume: 113, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Incidence; Male; Middle Aged; Prognosis; Pyrroles; Risk Factors; Time Factors	2014
[Effect of intensive pretreatment with atorvastatin calcium on outcomes of percutaneous coronary intervention in elderly patients with coronary heart disease]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2015, Volume: 35, Issue:2 Topics: Aged, 80 and over; Atorvastatin; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles	2015
Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. Journal of the American College of Cardiology, 2015, Apr-07, Volume: 65, Issue:13 Topics: Aged; Apolipoprotein B-100; Atorvastatin; Biomarkers; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidation-Reduction; Phospholipids; Pyrroles; Risk Factors	2015
Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels. Atherosclerosis. Supplements, 2015, Volume: 18 Topics: Adult; Atorvastatin; Biomarkers; Blood Component Removal; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Immunosorbent Techniques; Lipoprotein(a); Male; Middle Aged; Prospective Studies; Russia; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Up-Regulation	2015
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids in health and disease, 2015, Sep-04, Volume: 14 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides	2015
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial. Drugs & aging, 2015, Volume: 32, Issue:12 Topics: Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pravastatin; Renal Insufficiency, Chronic; Uric Acid	2015
Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level. Clinical cardiology, 2008, Volume: 31, Issue:6 Topics: Adiponectin; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Radioimmunoassay; Treatment Outcome	2008
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic proceedings, 2008, Volume: 83, Issue:8 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk; Treatment Outcome; United States	2008
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas Journal of the American College of Cardiology, 2008, Aug-19, Volume: 52, Issue:8 Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney international. Supplement, 2008, Issue:111 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; CD40 Ligand; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Triglycerides	2008
[Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA]. Kardiologiia, 2008, Volume: 48, Issue:11 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Research Design; Risk Factors; Safety; Time Factors; Treatment Outcome; Triglycerides	2008
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:3 Topics: Acute Coronary Syndrome; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Time Factors; Treatment Outcome	2009
Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2009, Volume: 19, Issue:7 Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Blood Coagulation; Carotid Artery Diseases; Coronary Disease; Cross-Sectional Studies; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Infarction; Plasma; Pyrroles; Sample Size; Thrombosis; Ultrasonography	2009
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:5 Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Follow-Up Studies; Glomerular Filtration Rate; Health Maintenance Organizations; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome	2009
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). The American journal of cardiology, 2009, Mar-01, Volume: 103, Issue:5 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Myocardial Infarction; Pyrroles; Simvastatin	2009
Coronary heart disease benefits from blood pressure and lipid-lowering. International journal of cardiology, 2009, Jun-26, Volume: 135, Issue:2 Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Risk Factors; Risk Reduction Behavior; Sodium Chloride Symporter Inhibitors	2009
Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. Journal of cardiology, 2009, Volume: 54, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Prospective Studies; Pyrroles; Research Design	2009
Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2 Topics: Adenosine Diphosphate; Aged; Aspirin; Atorvastatin; Clopidogrel; Comorbidity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Prospective Studies; Pyrroles; Ticlopidine	2010
Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. Journal of clinical pharmacology, 2010, Volume: 50, Issue:3 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Administration, Oral; Anticholesteremic Agents; Apoptosis; Atherosclerosis; Atorvastatin; CD13 Antigens; Coronary Disease; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Gene Expression; Heptanoic Acids; Humans; Lipid Metabolism; Male; Matrix Metalloproteinase 1; Middle Aged; Monocytes; Prolyl Oligopeptidases; Pyrroles; Receptors, Leptin; Reverse Transcriptase Polymerase Chain Reaction; Serine Endopeptidases; Time Factors; Treatment Outcome	2010
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk Metabolic syndrome and related disorders, 2009, Volume: 7, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circulation. Cardiovascular genetics, 2009, Volume: 2, Issue:2 Topics: Adult; Aged; Apolipoproteins E; Atorvastatin; Cohort Studies; Coronary Disease; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases	2009
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. Journal of the American College of Cardiology, 2009, Dec-15, Volume: 54, Issue:25 Topics: Angina, Unstable; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Pyrroles	2009
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). The American journal of cardiology, 2010, Feb-01, Volume: 105, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Coronary Restenosis; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Heart Diseases; Heart Failure; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Risk Factors; Treatment Outcome	2010
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2010, Volume: 41, Issue:3 Topics: Atorvastatin; Cholesterol; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Stroke	2010
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). The American journal of cardiology, 2010, Mar-01, Volume: 105, Issue:5 Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides	2010
Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clinical cardiology, 2010, Volume: 33, Issue:4 Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Disease; Diet, Fat-Restricted; Female; Glutathione; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome	2010
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial. International journal of clinical practice, 2010, Volume: 64, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Markov Chains; Medication Adherence; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Risk Factors	2010
Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. International journal of cardiology, 2011, Dec-01, Volume: 153, Issue:2 Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Racial Groups; Risk Factors; Sex Factors; Treatment Outcome; Young Adult	2011
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European heart journal, 2010, Volume: 31, Issue:23 Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome	2010
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome	2010
Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials). The American journal of cardiology, 2011, Jan-15, Volume: 107, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Smoking; Survival Rate; Treatment Outcome; United States	2011
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. Journal of the American College of Cardiology, 2011, Jan-04, Volume: 57, Issue:1 Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Retrospective Studies; Stroke; Time Factors	2011
Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. International angiology : a journal of the International Union of Angiology, 2011, Volume: 30, Issue:4 Topics: Atorvastatin; Biomarkers; Blood Pressure; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Czech Republic; Double-Blind Method; Drugs, Generic; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Poland; Pyrroles; Therapeutic Equivalency; Time Factors; Treatment Outcome	2011
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. European heart journal, 2012, Volume: 33, Issue:4 Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome	2012
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. European heart journal, 2011, Volume: 32, Issue:20 Topics: Adult; Aged; Atorvastatin; Cause of Death; Coronary Disease; Double-Blind Method; Early Termination of Clinical Trials; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome	2011
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. Journal of cardiology, 2012, Volume: 59, Issue:1 Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glucose Intolerance; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Oxidation-Reduction; Prospective Studies; Pyrroles	2012
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study. Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:5 Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Fasting; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2012
Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. Journal of the American College of Cardiology, 2012, May-15, Volume: 59, Issue:20 Topics: Aged; Atorvastatin; Biomarkers; Case-Control Studies; Coronary Disease; Double-Blind Method; Drug Delivery Systems; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Treatment Outcome	2012
Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease. American heart journal, 2012, Volume: 164, Issue:3 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Risk Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency	2012
No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design. Prostaglandins, leukotrienes, and essential fatty acids, 2012, Volume: 87, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Calcimycin; Calcium Ionophores; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukotriene B4; Male; Middle Aged; Neutrophil Activation; Neutrophils; Pyrroles	2012
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. Journal of the American College of Cardiology, 2013, Jan-15, Volume: 61, Issue:2 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke	2013
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current medical research and opinion, 2002, Volume: 18, Issue:4 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Cost-Benefit Analysis; Female; Greece; Heptanoic Acids; Humans; Male; Middle Aged; National Health Programs; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides	2002
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis, 2002, Volume: 164, Issue:2 Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome	2002
Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. The American journal of cardiology, 2002, Oct-01, Volume: 90, Issue:7 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dietary Fats; Dose-Response Relationship, Drug; Fasting; Female; Heptanoic Acids; Humans; Lipoprotein(a); Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides	2002
Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. Journal of lipid research, 2002, Volume: 43, Issue:10 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, HDL; Male; Middle Aged; Pyrroles	2002
Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. The Journal of laboratory and clinical medicine, 2003, Volume: 141, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholestanol; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols; Squalene; Sterols	2003
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis Lancet (London, England), 2003, Apr-05, Volume: 361, Issue:9364 Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors; Stroke	2003
Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Current medical research and opinion, 2003, Volume: 19, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles	2003
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin]. Kardiologiia, 2003, Volume: 43, Issue:1 Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors	2003
[Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis]. Kardiologiia, 2003, Volume: 43, Issue:6 Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Electrocardiography; Female; Heptanoic Acids; Homeostasis; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Syndrome; Time Factors	2003
Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism: clinical and experimental, 2003, Volume: 52, Issue:10 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-48; Apolipoproteins B; Area Under Curve; Atorvastatin; Chylomicrons; Coronary Disease; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Postprandial Period; Pyrroles; Receptors, LDL; Treatment Outcome; Triglycerides	2003
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Annals of medicine, 2003, Volume: 35, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins C; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides	2003
Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clinica chimica acta; international journal of clinical chemistry, 2003, Volume: 338, Issue:1-2 Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Coronary Disease; Culture Media, Conditioned; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Monocytes; Pyrroles; RNA, Messenger	2003
Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atherosclerosis. Supplements, 2003, Volume: 4, Issue:4 Topics: Acute Disease; Adult; Aged; Arginine; Atorvastatin; Biomarkers; Blood Glucose; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Statistics as Topic; Triglycerides	2003
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. The American journal of cardiology, 2004, Jan-01, Volume: 93, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides	2004
The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, Volume: 43, Issue:1 Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Brachial Artery; Carotid Artery, Common; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tunica Intima; Tunica Media; Ultrasonography	2004
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? The American journal of cardiology, 2004, Jan-15, Volume: 93, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke; Time Factors	2004
[Statin therapy for hypertensive patients]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2004, Jan-22, Volume: 124, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles	2004
Plasma antioxidative activity during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:1 Topics: Adult; Antioxidants; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pyrroles	2004
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation, 2004, Mar-23, Volume: 109, Issue:11 Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome	2004
Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clinical chemistry, 2004, Volume: 50, Issue:4 Topics: Acute Disease; Angina, Unstable; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Pyrroles	2004
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. American heart journal, 2004, Volume: 147, Issue:4 Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2004
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease]. Revue medicale de Liege, 2004, Volume: 59, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic	2004
Treating to hypertension targets. Heart (British Cardiac Society), 2004, Volume: 90 Suppl 4 Topics: Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Determination; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles	2004
Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current medical research and opinion, 2004, Volume: 20, Issue:5 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Greece; Heptanoic Acids; Humans; Male; Middle Aged; National Health Programs; Proportional Hazards Models; Pyrroles; Treatment Outcome	2004
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Journal of clinical pathology, 2004, Volume: 57, Issue:7 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, HDL; Coronary Disease; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles	2004
Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides	2004
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation, 2004, Aug-31, Volume: 110, Issue:9 Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Cilostazol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Tetrazoles; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional	2004
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. The American journal of cardiology, 2004, Sep-15, Volume: 94, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Research Design; Simvastatin; Treatment Outcome	2004
Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current medical research and opinion, 2004, Volume: 20, Issue:9 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Practice Guidelines as Topic; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate	2004
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation, 2004, Oct-19, Volume: 110, Issue:16 Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment	2004
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. Journal of the American College of Cardiology, 2004, Nov-02, Volume: 44, Issue:9 Topics: Adult; Aged; Ambulatory Care Facilities; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Disease Management; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Managed Care Programs; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides; United States	2004
C-reactive protein levels and outcomes after statin therapy. The New England journal of medicine, 2005, Jan-06, Volume: 352, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention	2005
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clinical therapeutics, 2004, Volume: 26, Issue:11 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2004
Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. American heart journal, 2005, Volume: 149, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides	2005
Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation, 2005, Feb-01, Volume: 111, Issue:4 Topics: Adenosine Diphosphate; Atorvastatin; Biomarkers; Blood Coagulation; Blood Platelets; CD40 Ligand; Collagen; Coronary Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Multifactorial Inheritance; Peptide Fragments; Prothrombin; Pyrroles; Solubility; Thrombin; Thromboplastin; Treatment Outcome	2005
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England journal of medicine, 2005, Apr-07, Volume: 352, Issue:14 Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prospective Studies; Pyrroles; Risk; Triglycerides	2005
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis Drugs, 2004, Volume: 64 Suppl 2 Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Disease; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom	2004
Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor. Thrombosis research, 2005, Volume: 115, Issue:6 Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Lipoproteins; Male; Middle Aged; Prothrombin; Pyrroles; Thrombin; Thromboplastin; Treatment Outcome	2005
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. International journal of cardiology, 2005, Apr-20, Volume: 100, Issue:2 Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. American heart journal, 2005, Volume: 149, Issue:3 Topics: Acute Disease; Acute-Phase Proteins; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Female; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Secondary Prevention; Syndrome	2005
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. International journal of clinical practice, 2005, Volume: 59, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Safety	2005
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:3 Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Pyrroles; Vascular Diseases	2005
Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients. NMR in biomedicine, 2005, Volume: 18, Issue:7 Topics: Aged; Atorvastatin; Cholesterol; Cluster Analysis; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Nuclear Magnetic Resonance, Biomolecular; Principal Component Analysis; Pyrroles; Reproducibility of Results; Simvastatin	2005
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. International journal of cardiology, 2005, Oct-10, Volume: 104, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides	2005
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes care, 2005, Volume: 28, Issue:10 Topics: Acute Disease; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Metabolic Syndrome; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Prognosis; Pyrroles; Recurrence; Risk Factors; Treatment Outcome	2005
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). The American journal of cardiology, 2005, Nov-01, Volume: 96, Issue:9 Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Syndrome; Ultrasonography; Vasodilation	2005
The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. International journal of cardiology, 2006, Aug-28, Volume: 111, Issue:3 Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides	2006
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. International journal of clinical practice, 2005, Volume: 59, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome	2005
Achieving lipid goals in real life: the Dutch DISCOVERY study. International journal of clinical practice, 2005, Volume: 59, Issue:12 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides	2005
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed : Medscape general medicine, 2005, Jul-14, Volume: 7, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin	2005
The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clinica chimica acta; international journal of clinical chemistry, 2006, Volume: 368, Issue:1-2 Topics: Acute Disease; Atorvastatin; C-Reactive Protein; Coronary Disease; Female; Heptanoic Acids; Humans; Lipid Metabolism; Middle Aged; Peroxidase; Pyrroles; Syndrome	2006
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Circulation, 2006, Apr-11, Volume: 113, Issue:14 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome	2006
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. American heart journal, 2006, Volume: 151, Issue:5 Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2006
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). The American journal of cardiology, 2006, Jun-01, Volume: 97, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors	2006
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes care, 2006, Volume: 29, Issue:6 Topics: Aged; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides	2006
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (London, England), 2006, Sep-09, Volume: 368, Issue:9539 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors	2006
Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-C Journal of the American College of Cardiology, 2006, Oct-17, Volume: 48, Issue:8 Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiotonic Agents; Cell Adhesion Molecules; Coronary Disease; E-Selectin; Heart Injuries; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Intercellular Adhesion Molecule-1; Multicenter Studies as Topic; Pyrroles; Vascular Cell Adhesion Molecule-1	2006
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes care, 2006, Volume: 29, Issue:11 Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke	2006
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology, 2006, Nov-07, Volume: 48, Issue:9 Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles	2006
Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. Journal of cardiovascular pharmacology, 2006, Volume: 48, Issue:4 Topics: Adult; Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Male; Middle Aged; Neutrophils; Primary Prevention; Pyrroles; Superoxides; Zymosan	2006
[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]. Zhonghua yi xue za zhi, 2006, Sep-12, Volume: 86, Issue:34 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Female; Headache; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Niacin; Pyrroles; Treatment Outcome; Triglycerides	2006
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation, 2007, Feb-13, Volume: 115, Issue:6 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pravastatin; Pyrroles; Sex Characteristics	2007
Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease. Wiener medizinische Wochenschrift (1946), 2007, Volume: 157, Issue:3-4 Topics: Anticholesteremic Agents; Atorvastatin; Brachial Artery; C-Reactive Protein; Coronary Disease; Double-Blind Method; E-Selectin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pyrroles; Vasodilation	2007
Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart (British Cardiac Society), 2007, Volume: 93, Issue:8 Topics: Aged; Atorvastatin; C-Reactive Protein; Carotid Arteries; Carotid Artery Diseases; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-18; Interleukin-6; Interleukin-8; Lipids; Male; Middle Aged; Pyrroles; Tumor Necrosis Factor-alpha; Tunica Intima; Tunica Media	2007
Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients. Journal of the Indian Medical Association, 2006, Volume: 104, Issue:9 Topics: Adult; Apolipoproteins B; Atorvastatin; Biomarkers; Coronary Disease; Drug Administration Schedule; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Nephelometry and Turbidimetry; Pyrroles; Simvastatin; Treatment Outcome	2006
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. Journal of the American College of Cardiology, 2007, Mar-27, Volume: 49, Issue:12 Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Syndrome; Time Factors; Treatment Outcome	2007
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome	2007
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides	2007
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clinic proceedings, 2007, Volume: 82, Issue:5 Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Creatinine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Managed Care Programs; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2007
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). The American journal of cardiology, 2007, Jun-01, Volume: 99, Issue:11 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Asian People; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States	2007
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Annals of internal medicine, 2007, Jul-03, Volume: 147, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Treatment Outcome; Triglycerides	2007
Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study. Current medical research and opinion, 2007, Volume: 23, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome	2007
Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:10 Topics: Adult; Atorvastatin; Brachial Artery; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Pyrroles; Risk Factors; Severity of Illness Index; Ultrasonography; Vasodilation	2007
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). The American journal of cardiology, 2007, Sep-01, Volume: 100, Issue:5 Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Assessment; Safety; Sex Factors; Stroke; Time Factors; Treatment Outcome	2007
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. The New England journal of medicine, 2007, Sep-27, Volume: 357, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Pyrroles; Risk	2007
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. Journal of thrombosis and thrombolysis, 2009, Volume: 27, Issue:1 Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Collagen; Coronary Disease; Diabetes Complications; Drug Resistance; Epinephrine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyrroles; Smoking	2009
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Pyrroles	2007
Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mortality; Pyrroles; Quinolines	2007
SPARCL: the glimmer of statins for stroke risk reduction. Current atherosclerosis reports, 2007, Volume: 9, Issue:5 Topics: Atorvastatin; Coronary Disease; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Stroke	2007
Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study. Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:12 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional	2007
Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart (British Cardiac Society), 2008, Volume: 94, Issue:4 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrroles; Sex Factors; Survival Analysis; Treatment Outcome; United States	2008
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European heart journal, 2008, Volume: 29, Issue:4 Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke	2008
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thrombosis and haemostasis, 2008, Volume: 99, Issue:1 Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Simvastatin; Stents; Ticlopidine; Time Factors; Treatment Outcome	2008
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology, 2008, Jan-29, Volume: 51, Issue:4 Topics: Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Treatment Outcome	2008
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology, 2008, Feb-19, Volume: 51, Issue:7 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides	2008
Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Current medical research and opinion, 2008, Volume: 24, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Outcome Assessment, Health Care; Pyrroles; Sex Factors	2008
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology, 2008, Volume: 111, Issue:4 Topics: Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Disease; European Union; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2008
The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Systole; Time Factors; Treatment Outcome	2008
Use of lipid-modulating drugs in complicated course of coronary heart disease. Bulletin of experimental biology and medicine, 2007, Volume: 144, Issue:3 Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor	2007
Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). The American journal of cardiology, 1997, Nov-01, Volume: 80, Issue:9 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Research Design; Stents	1997
Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. The American journal of cardiology, 1998, Sep-01, Volume: 82, Issue:5 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Research Design	1998
Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. The Journal of family practice, 1998, Volume: 47, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Risk Factors	1998
Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet (London, England), 1999, Jan-09, Volume: 353, Issue:9147 Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides	1999
Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. Journal of internal medicine, 1999, Volume: 245, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Treatment Outcome	1999
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. The New England journal of medicine, 1999, Jul-08, Volume: 341, Issue:2 Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Quality of Life; Risk; Treatment Outcome	1999
Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). The American journal of cardiology, 1999, Jul-01, Volume: 84, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diet, Fat-Restricted; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Safety; Simvastatin; Time Factors	1999
An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study. International journal of clinical practice, 1999, Volume: 53, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Family Practice; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome	1999
Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial. The Canadian journal of cardiology, 2000, Volume: 16 Suppl A Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Coronary Disease; Decision Making; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Safety; Survival Rate; Treatment Outcome	2000
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease. Transplantation proceedings, 2000, Volume: 32, Issue:2 Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides	2000
Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. American heart journal, 2001, Volume: 141, Issue:3 Topics: Atorvastatin; Carotid Artery, Common; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Tunica Intima; Tunica Media	2001
Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis, 2001, Volume: 155, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin	2001
Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. Clinical therapeutics, 2001, Volume: 23, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost Control; Drug Costs; Europe; Heptanoic Acids; Humans; Hypercholesterolemia; Peripheral Vascular Diseases; Pyrroles; Simvastatin	2001
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy, 2001, Volume: 21, Issue:4 Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome	2001
The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial. Acta cardiologica, 2001, Volume: 56, Issue:2 Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles	2001
Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation, 2001, Jun-19, Volume: 103, Issue:24 Topics: Adult; Anticholesteremic Agents; Antigens, CD; Atorvastatin; Blood Cells; Cell Count; Coronary Disease; Endothelium, Vascular; Female; Hematopoietic Stem Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Stem Cells	2001
The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1. Journal of clinical pharmacology, 2001, Volume: 41, Issue:7 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Serine Proteinase Inhibitors; Simvastatin	2001
Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation, 2001, Jul-24, Volume: 104, Issue:4 Topics: Anticholesteremic Agents; Arteriosclerosis; Arthralgia; Atorvastatin; Butyrates; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Coronary Disease; Creatinine; Exanthema; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Dropouts; Pyrroles; Treatment Outcome; Triglycerides; Ultrasonography, Interventional; Venous Thrombosis	2001
The effect of pravastatin and atorvastatin on coenzyme Q10. American heart journal, 2001, Volume: 142, Issue:2 Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Coenzymes; Coronary Disease; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Triglycerides; Ubiquinone	2001
Is aggressive lipid-lowering therapy preferable to angioplasty in stable coronary artery disease? The Medical journal of Australia, 2001, Nov-05, Volume: 175, Issue:9 Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles	2001
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. The American journal of cardiology, 2002, Mar-15, Volume: 89, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Patient Compliance; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome	2002
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis, 2002, Volume: 162, Issue:1 Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Evaluation; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Male; Norway; P-Selectin; Pyrroles; Simvastatin; Statistics as Topic; Thrombomodulin; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides; Vascular Cell Adhesion Molecule-1; von Willebrand Factor	2002
The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. Journal of clinical apheresis, 2002, Volume: 17, Issue:1 Topics: Adsorption; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Blood Component Removal; Cell Adhesion; Chelating Agents; Chemical Precipitation; Combined Modality Therapy; Coronary Disease; Dextran Sulfate; E-Selectin; Edetic Acid; Female; Hematocrit; Heparin; Heptanoic Acids; Humans; Hyperlipoproteinemias; Intercellular Adhesion Molecule-1; Lipids; Lipoproteins, LDL; Male; Pyrroles; Vascular Cell Adhesion Molecule-1	2002
Short-term effects of atorvastatin on C-reactive protein. European heart journal, 2002, Volume: 23, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Pyrroles; Sensitivity and Specificity; Switzerland; Time Factors; Triglycerides	2002
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. Journal of internal medicine, 2002, Volume: 251, Issue:6 Topics: Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles	2002
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thrombosis research, 2002, Feb-15, Volume: 105, Issue:4 Topics: Atorvastatin; Blood Coagulation; Coronary Disease; Double-Blind Method; Female; Fibrinolysis; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyrroles; Simvastatin; Time Factors	2002
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:4 Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Platelet Aggregation; Pyrroles; Thromboplastin; Thrombosis	2002

Other Studies

173 other study(ies) available for atorvastatin and Coronary Disease

Article	Year
The ABCB1 C3435T Polymorphism is Associated with Triglyceride Reduction in Atorvastatin-treated Uygur Patients with Coronary Heart Disease and Dyslipidemia: An Observational Study. Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:9 Topics: Apolipoproteins B; Apolipoproteins E; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Humans; Male; Polymorphism, Genetic; Triglycerides	2023
Combined QSAR Model and Chemical Similarity Search for Novel HMGCoA Reductase Inhibitors for Coronary Heart Disease. Current computer-aided drug design, 2020, Volume: 16, Issue:4 Topics: Atorvastatin; Computer Simulation; Coronary Disease; Drug Discovery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quantitative Structure-Activity Relationship	2020
A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease. British journal of clinical pharmacology, 2019, Volume: 85, Issue:12 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chromatography, Liquid; Coronary Disease; Directly Observed Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Medication Adherence; Tandem Mass Spectrometry	2019
Protective effects of Naoxintong capsule alone and in combination with ticagrelor and atorvastatin in rats with Qi deficiency and blood stasis syndrome. Pharmaceutical biology, 2020, Volume: 58, Issue:1 Topics: Animals; Atorvastatin; Cardiotonic Agents; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Male; Qi; Rats; Rats, Sprague-Dawley; Ticagrelor	2020
Evaluation of efficacy and safety of combined rosuvastatin and atorvastatin in treating with coronary heart disease: A protocol for systematic review and meta-analysis. Medicine, 2021, Jun-18, Volume: 100, Issue:24 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Therapy, Combination; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Systematic Reviews as Topic; Treatment Outcome	2021
Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal? American journal of physiology. Gastrointestinal and liver physiology, 2017, 06-01, Volume: 312, Issue:6 Topics: Atorvastatin; Comorbidity; Coronary Disease; Evidence-Based Medicine; Humans; Longitudinal Studies; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Factors; Rosuvastatin Calcium; Treatment Outcome	2017
[Atorvastatin therapy under clinical practice conditions - which LDL-C levels are achieved in patients at very high cardiovascular risk?] Deutsche medizinische Wochenschrift (1946), 2017, Volume: 142, Issue:16 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Risk	2017
More on carotid atherosclerosis and ezetimibe. International angiology : a journal of the International Union of Angiology, 2017, Volume: 36, Issue:6 Topics: Atorvastatin; Carotid Artery Diseases; Carotid Stenosis; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans	2017
Galectin-3 in patients with coronary heart disease and atrial fibrillation. Clinica chimica acta; international journal of clinical chemistry, 2018, Volume: 478 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Blood Proteins; Catheter Ablation; Coronary Disease; Female; Fibrosis; Galectin 3; Galectins; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Severity of Illness Index; Stroke Volume	2018
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). The American journal of cardiology, 2018, 04-15, Volume: 121, Issue:8 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; PCSK9 Inhibitors; Peripheral Arterial Disease; Risk; Rosuvastatin Calcium; Simvastatin; Stroke; Treatment Outcome	2018
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 2018, 08-21, Volume: 138, Issue:8 Topics: Adult; Aged; Atorvastatin; Biomarkers; Cause of Death; Cholesterol; Cholesterol, LDL; Coronary Disease; Disease Progression; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triglycerides	2018
Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER. Scientific reports, 2019, 05-22, Volume: 9, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Benzoates; Benzylamines; Berberine; Cholesterol; Chromosomes, Human, Pair 11; Coronary Disease; Gene Expression Regulation; Genome-Wide Association Study; Hep G2 Cells; Hepatocyte Nuclear Factor 1-alpha; Hepatocytes; Histone Code; Histone Demethylases; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Proprotein Convertase 9; Protein Binding; Protein Interaction Mapping; RNA Interference; RNA, Long Noncoding; RNA, Small Interfering	2019
Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiologia polska, 2013, Volume: 71, Issue:10 Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides	2013
Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin. Rheumatology international, 2014, Volume: 34, Issue:8 Topics: Absorptiometry, Photon; Aged; Atorvastatin; Bone Density; Coronary Disease; Female; Femur; Gene Frequency; Genotype; Geranyltranstransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Time Factors; Treatment Outcome	2014
Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. Journal of medical economics, 2015, Volume: 18, Issue:8 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Lipids; Male; Middle Aged; Portugal; Quality-Adjusted Life Years; Risk Factors; Rosuvastatin Calcium; Smoking	2015
Lipid biomarkers and cardiovascular risk: which path to take at the fork in the road? Journal of the American College of Cardiology, 2015, Apr-07, Volume: 65, Issue:13 Topics: Apolipoprotein B-100; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Phospholipids; Pyrroles	2015
The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids in health and disease, 2015, Oct-09, Volume: 14 Topics: Adult; Aged; Apolipoprotein C-III; Atorvastatin; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Triglycerides	2015
[Polypill for secondary coronary heart disease prevention]. MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22 Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Medication Adherence; Ramipril	2015
[Combination drug improves adherence]. MMW Fortschritte der Medizin, 2016, Apr-28, Volume: 158, Issue:8 Topics: Aspirin; Atorvastatin; Capsules; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Ramipril; Secondary Prevention	2016
Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA. European heart journal, 2008, Volume: 29, Issue:15 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Glycation End Products, Advanced; Heptanoic Acids; Humans; Pyrroles	2008
Does atorvastatin affect androgen levels in men in the era of very-low LDL targeting therapy? Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2009, Volume: 117, Issue:2 Topics: Androgens; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles	2009
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl]. MMW Fortschritte der Medizin, 2008, Jun-05, Volume: 150, Issue:23 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin	2008
Effect of atorvastatin on hs-CRP in acute coronary syndrome. British journal of clinical pharmacology, 2008, Volume: 66, Issue:3 Topics: Acute Coronary Syndrome; Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome	2008
Intensive lipid intervention in the post-ENHANCE era. Mayo Clinic proceedings, 2008, Volume: 83, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology, 2009, Feb-24, Volume: 72, Issue:8 Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Risk Assessment; Stroke	2009
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2008, Volume: 39, Issue:12 Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Stenosis; Cerebral Hemorrhage; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Treatment Outcome	2008
[Vascular prevention after cerebral infarct or transient ischemic accident. Recommendations. March, 2008]. Revue neurologique, 2008, Volume: 164 Spec No 3 Topics: Anticholesteremic Agents; Atorvastatin; Brain; Cerebral Infarction; Cerebrovascular Circulation; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Time Factors	2008
Phospholipase A2 inhibitors in atherosclerosis: the race is on. Lancet (London, England), 2009, Feb-21, Volume: 373, Issue:9664 Topics: Atorvastatin; Benzaldehydes; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oximes; Phospholipases A2, Secretory; Pyrroles	2009
Statins: not just for the young or the faint of heart. Neurology, 2009, Feb-24, Volume: 72, Issue:8 Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke	2009
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of hypertension, 2009, Volume: 27, Issue:5 Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome	2009
Statin effects on LDL and HDL cholesterol in South Asian and white populations. Journal of clinical pharmacology, 2009, Volume: 49, Issue:7 Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Linear Models; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; White People	2009
Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting. Perfusion, 2009, Volume: 24, Issue:4 Topics: Aged; Antioxidants; Aryldialkylphosphatase; Atorvastatin; Carboxylic Ester Hydrolases; Coronary Artery Bypass; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidants; Oxidative Stress; Preoperative Care; Pyrroles	2009
Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease. Journal of atherosclerosis and thrombosis, 2010, Jul-30, Volume: 17, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Risk Factors; Triglycerides	2010
Approach to the patient who is intolerant of statin therapy. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:5 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Coronary Disease; Diltiazem; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Pyrroles; Simvastatin	2010
Cholesteryl ester transfer protein antagonism by drugs--a poor choice. Clinical chemistry, 2010, Volume: 56, Issue:10 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Polymorphism, Genetic; Pyrroles; Quinolines; Risk	2010
The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clinical and experimental immunology, 2011, Volume: 164, Issue:2 Topics: Animals; Antigens, Bacterial; Arteritis; Atorvastatin; Cell Wall; Coronary Aneurysm; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lacticaseibacillus casei; Lymphocyte Activation; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mucocutaneous Lymph Node Syndrome; Pyrroles; Specific Pathogen-Free Organisms; Superantigens; Tumor Necrosis Factor-alpha	2011
Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. The International journal of pharmacy practice, 2011, Volume: 19, Issue:2 Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Electronic Health Records; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Primary Prevention; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Thailand	2011
Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol. International journal of cardiology, 2011, Jun-02, Volume: 149, Issue:2 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors	2011
Lifestyle changes and 14-year change in high-density lipoprotein cholesterol in a cohort of male physicians. American heart journal, 2011, Volume: 161, Issue:4 Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Risk Reduction Behavior; Stroke; Time Factors; Treatment Outcome	2011
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients. The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. European heart journal, 2012, Volume: 33, Issue:4 Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Stroke	2012
[Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm]. Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V..., 2012, Volume: 44, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Bezafibrate; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pyrroles	2012
Statins and glycaemic control--a cause for concern? Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:5 Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2012
Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion. Chinese medical journal, 2012, Volume: 125, Issue:14 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cystatin C; Female; Heptanoic Acids; Humans; Male; Middle Aged; Probucol; Prospective Studies; Pyrroles	2012
[Atorvastatin and oxidative stress in coronary heart disease with obesity]. Klinicheskaia meditsina, 2012, Volume: 90, Issue:10 Topics: Adult; Aged; Antioxidants; Atorvastatin; Case-Control Studies; Coronary Disease; Dyslipidemias; Electrocardiography, Ambulatory; Electron Spin Resonance Spectroscopy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipids; Middle Aged; Obesity; Oxidative Stress; Pyrroles	2012
Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2002, Volume: 12, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Regression Analysis; Triglycerides	2002
The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current medical research and opinion, 2002, Volume: 18, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Female; Greece; Heptanoic Acids; Humans; Male; Middle Aged; National Health Programs; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides	2002
Aggressive lipid-lowering in stable patients with coronary artery disease. The Journal of family practice, 1999, Volume: 48, Issue:10 Topics: Angioplasty; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Male; Multicenter Studies as Topic; Myocardial Ischemia; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic	1999
PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. Atherosclerosis, 2003, Volume: 166, Issue:1 Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Disease; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pregnancy-Associated Plasma Protein-A; Pyrroles	2003
[Ezetimib plus statin combination. A strong duo]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin	2002
Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current medical research and opinion, 2002, Volume: 18, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Europe; Guideline Adherence; Heptanoic Acids; Humans; Myocardial Infarction; Practice Guidelines as Topic; Preventive Health Services; Pyrroles; Societies; Stroke; United Kingdom	2002
Benefits of atorvastatin in cholesterol lowering. Current atherosclerosis reports, 2003, Volume: 5, Issue:2 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides	2003
[Effect of high doses of atorvastatin on the endothelial function of the coronary arteries]. Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:1 Topics: Acetylcholine; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Data Interpretation, Statistical; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles; Regression Analysis; Time Factors; Triglycerides	2003
Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. The American journal of cardiology, 2003, May-01, Volume: 91, Issue:9 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Atorvastatin; Biphenyl Compounds; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Interleukin-6; Irbesartan; Isoquinolines; Male; Middle Aged; Monocytes; Platelet Aggregation Inhibitors; Pyrroles; Quinapril; Tetrahydroisoquinolines; Tetrazoles	2003
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes care, 2003, Volume: 26, Issue:6 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States	2003
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?]. MMW Fortschritte der Medizin, 2003, May-22, Volume: 145, Issue:21 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors	2003
In light of ALLHAT and ASCOT: are there benefits of statins as add-on treatment in hypertensives? Blood pressure, 2003, Volume: 12, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2003
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. The American journal of cardiology, 2003, Aug-01, Volume: 92, Issue:3 Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Drug Utilization; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Registries; Stroke; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome	2003
[Statin soon to become standard addition to antihypertensive therapy? Better prevention of coronary heart disease for hypertensive patients]. MMW Fortschritte der Medizin, 2003, Jul-24, Volume: 145, Issue:29-30 Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome	2003
No absolutes. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Sep-30, Volume: 169, Issue:7 Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Risk; Sample Size	2003
Statin use is associated with enhanced collateralization of severely diseased coronary arteries. American heart journal, 2003, Volume: 146, Issue:5 Topics: Aged; Aspirin; Atorvastatin; Calcium Channels; Collateral Circulation; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Pyrroles; Retrospective Studies	2003
Lack of adverse clopidogrel-atorvastatin clinical interaction. The American journal of cardiology, 2004, Mar-01, Volume: 93, Issue:5 Topics: Atorvastatin; Clopidogrel; Coronary Disease; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Research Design; Ticlopidine	2004
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, Volume: 43, Issue:4 Topics: Aged; Atorvastatin; Coronary Disease; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Uric Acid	2004
Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation, 2004, May-11, Volume: 109, Issue:18 Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; CD4 Lymphocyte Count; Coronary Disease; Epichlorohydrin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Imidazoles; Immunophenotyping; Male; Prospective Studies; Pyrroles; Resins, Synthetic; Th1 Cells; Th2 Cells	2004
Believe-it then PROVE-IT. International journal of clinical practice, 2004, Volume: 58, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Reference Values	2004
Update on statins. Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing, 2004, Volume: 22, Issue:2 Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. The American journal of cardiology, 2004, Jul-15, Volume: 94, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Angiography; Coronary Disease; Endothelium, Vascular; Female; Hemostasis; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Male; Middle Aged; Peptide Fragments; Prospective Studies; Prothrombin; Pyrroles; Tissue Plasminogen Activator	2004
The effect of atorvastatin on platelet function in patients with coronary artery disease. Acta cardiologica, 2004, Volume: 59, Issue:3 Topics: Atorvastatin; Blood Platelets; Case-Control Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Prospective Studies; Pyrroles	2004
Battle of the statins, or how the news media can change patient care. JAAPA : official journal of the American Academy of Physician Assistants, 2004, Volume: 17, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Media; Practice Patterns, Physicians'; Pravastatin; Pyrroles	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles	2004
Avoid angioplasty by lowering cholesterol? Health news (Waltham, Mass.), 1999, Aug-15, Volume: 5, Issue:10 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic	1999
[Cost effectiveness of atorvastatin for prevention of coronary disease--an analysis of the ASCOT study. Re: the article from DMW 25/26 2004]. Deutsche medizinische Wochenschrift (1946), 2004, Sep-10, Volume: 129, Issue:37 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Heptanoic Acids; Humans; Pyrroles; Treatment Outcome	2004
[Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)]. MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Approval; Drugs, Generic; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles	2004
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. Atherosclerosis. Supplements, 2004, Volume: 5, Issue:3 Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American heart journal, 2004, Volume: 148, Issue:6 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Pravastatin; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design	2004
[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin]. Der Internist, 2005, Volume: 46, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome	2005
PROVE IT then believe it. International journal of clinical practice, 2005, Volume: 59, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles	2005
Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals? The New England journal of medicine, 2005, Apr-07, Volume: 352, Issue:14 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk	2005
[Coronary disease patient has already LDL of 100 mg/dl. Why lipid lowering is still worthwhile]. MMW Fortschritte der Medizin, 2005, Mar-24, Volume: 147, Issue:12 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Placebos; Pyrroles; Risk Factors; Time Factors	2005
Statins in acute coronary syndromes: the sooner, the better? American heart journal, 2005, Volume: 149, Issue:3 Topics: Acute Disease; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Secondary Prevention; Syndrome	2005
Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS. Journal of managed care pharmacy : JMCP, 2005, Volume: 11, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles	2005
Letter regarding article by Tsimikas et al, "high-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial". Circulation, 2005, May-10, Volume: 111, Issue:18 Topics: Acute Disease; Antigen-Antibody Complex; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Phospholipids; Pyrroles; Reagent Kits, Diagnostic; Reproducibility of Results	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Simvastatin	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Rhabdomyolysis	2005
The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets, 2005, Volume: 16, Issue:5 Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Blood Platelets; CD40 Ligand; Cholesterol; Cholesterol, LDL; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Triglycerides	2005
[Effect of maximum dose of atorvastatin on inflammation, thrombogenesis and fibrinolysis in high-risk patients with ischemic heart disease]. Revista espanola de cardiologia, 2005, Volume: 58, Issue:8 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Data Interpretation, Statistical; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolysis; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunochemistry; Lipids; Male; Middle Aged; Prothrombin; Pyrroles; Risk Factors; Time Factors	2005
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly]. MMW Fortschritte der Medizin, 2005, Aug-18, Volume: 147, Issue:33-34 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors	2005
[To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too]. MMW Fortschritte der Medizin, 2005, Aug-18, Volume: 147, Issue:33-34 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Triglycerides	2005
Interleukin-6 (IL-6)-174 G/C polymorphism--lack of association with inflammatory and haemostatic variables in patients with coronary heart disease treated with atorvastatin and quinapril. International journal of cardiology, 2006, Sep-10, Volume: 112, Issue:1 Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biomarkers; Coronary Disease; Cytosine; Drug Therapy, Combination; Genotype; Guanine; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Quinapril; Tetrahydroisoquinolines; Treatment Outcome	2006
Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. The American journal of medicine, 2005, Volume: 118 Suppl 12A Topics: Adolescent; Adult; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic	2005
HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients. Thrombosis research, 2006, Volume: 118, Issue:5 Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Prothrombin; Pyrroles; Thrombin; Thromboplastin; Treatment Outcome	2006
Statins for high-risk patients without heart disease or high cholesterol. The Medical letter on drugs and therapeutics, 2006, Jan-02, Volume: 48, Issue:1225 Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke	2006
Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease. Current atherosclerosis reports, 2006, Volume: 8, Issue:1 Topics: Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk; Triglycerides	2006
C-reactive protein levels and outcomes after statin therapy. Current atherosclerosis reports, 2006, Volume: 8, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors	2006
Effect of statin treatment on coronary collateral development in patients with diabetes mellitus. The American journal of cardiology, 2006, Mar-15, Volume: 97, Issue:6 Topics: Angina Pectoris; Atorvastatin; Cholesterol, LDL; Collateral Circulation; Coronary Angiography; Coronary Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin	2006
Medication costs as a primary cause of nonadherence in the elderly. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2006, Volume: 21, Issue:2 Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Prescriptions; Drugs, Generic; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Metoprolol; Patient Compliance; Pharmacists; Pyrroles; Self Administration	2006
Statins and antioxidant vitamins: should co-administration be avoided? Journal of the American College of Cardiology, 2006, Mar-21, Volume: 47, Issue:6 Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Calcinosis; Cardiovascular Diseases; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Vitamin E	2006
The logistic transform for bounded outcome scores. Biostatistics (Oxford, England), 2007, Volume: 8, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Computer Simulation; Coronary Disease; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Models, Statistical; Patient Compliance; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Tissue Plasminogen Activator	2007
Concurrent use of clopidogrel (Plavix) and atorvasatin (Lipitor) is contraindicated. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2006, Volume: 96, Issue:4 Topics: Atorvastatin; Clopidogrel; Contraindications; Coronary Disease; Drug Incompatibility; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine	2006
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain	2006
[Regression of a large lipid-rich pool in the coronary artery during treatment with statin detected by intravascular ultrasound: a case report]. Journal of cardiology, 2006, Volume: 47, Issue:6 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Stents; Ultrasonography, Interventional	2006
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data. American heart journal, 2006, Volume: 152, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin	2006
[For coronary disease patients is certain: the lower the LDL the better]. MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Odds Ratio; Pravastatin; Pyrroles; Simvastatin; Time Factors; Treatment Outcome	2006
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?]. MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional	2006
Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia. Journal of the National Medical Association, 2006, Volume: 98, Issue:8 Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Coagulation; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome	2006
High-dose statins for diabetes. Health news (Waltham, Mass.), 2006, Volume: 12, Issue:8 Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles	2006
Does the metabolic syndrome help to select patients requiring high statin dose? Lancet (London, England), 2006, Sep-09, Volume: 368, Issue:9539 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Incidence; Metabolic Syndrome; Patient Selection; Pyrroles; Risk Assessment; Risk Factors	2006
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluati Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:1 Topics: Aged; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Creatinine; Female; Glomerular Filtration Rate; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Uric Acid	2007
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Diabetes care, 2006, Volume: 29, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles	2006
Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Coronary Disease; Female; Finland; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome	2006
Impact of high dose statin trials on hospital prescribers. European journal of clinical pharmacology, 2007, Volume: 63, Issue:1 Topics: Aged; Atorvastatin; Cohort Studies; Coronary Disease; Databases, Factual; Drug Prescriptions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Patient Discharge; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic	2007
Statin therapy after stroke or transient ischemic attack. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk; Secondary Prevention; Stroke	2006
The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart and vessels, 2006, Volume: 21, Issue:5 Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Serum Amyloid A Protein; Statistics as Topic; Syndrome; Treatment Outcome; Triglycerides	2006
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:3 Topics: Angioplasty, Balloon, Coronary; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biopsy, Needle; Cells, Cultured; Chemokine CCL19; Chemokine CCL21; Chemokines, CC; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Heptanoic Acids; Humans; Immunohistochemistry; In Vitro Techniques; Leukocytes, Mononuclear; Mice; Mice, Transgenic; Prognosis; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Reference Values; Risk Factors; RNA, Messenger; Sensitivity and Specificity; Simvastatin; Treatment Outcome	2007
Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiologia polska, 2006, Volume: 64, Issue:12 Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Premedication; Pyrroles; Retrospective Studies; Syndrome; Treatment Outcome	2006
Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Randomized Controlled Trials as Topic	2007
Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Aged; Atorvastatin; Coronary Disease; Diet, Mediterranean; Female; Heptanoic Acids; Humans; Life Style; Metabolic Syndrome; Pyrroles	2007
Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Ethanol; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles	2007
Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Aged; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Male; Medical Audit; Middle Aged; Patient Readmission; Pyrroles; Simvastatin; United Kingdom	2007
Diabetes and residual risk of coronary heart disease. Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin	2007
Statin therapy and the elderly: SAGE advice? Circulation, 2007, Feb-13, Volume: 115, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Pyrroles	2007
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart (British Cardiac Society), 2007, Volume: 93, Issue:8 Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome	2007
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective. Current medical research and opinion, 2007, Volume: 23, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus; Drug Costs; Female; Heptanoic Acids; Humans; Male; Models, Theoretical; Pyrroles; Simvastatin; United States	2007
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"]. Revue medicale de Liege, 2007, Volume: 62, Issue:4 Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States	2007
Reducing myocardial injury by minimizing imbalance between oxygen supply and demand. Anesthesiology, 2007, Volume: 107, Issue:1 Topics: Anesthesiology; Animals; Atorvastatin; Blood Pressure; Cardiovascular Agents; Coronary Disease; Dogs; Heart Diseases; Heart Rate; Heptanoic Acids; History, 20th Century; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Myocardial Revascularization; Necrosis; Oxygen; Pyrroles	2007
Summaries for patients. High- or low-dose atorvastatin in elderly patients with stable coronary artery disease. Annals of internal medicine, 2007, Jul-03, Volume: 147, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Treatment Outcome; Triglycerides	2007
Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids, 2007, Volume: 42, Issue:11 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fasting; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regression Analysis; Risk Factors; Triglycerides	2007
HMG-CoA reductase inhibitors and renal function. Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Coronary Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lipoproteins, LDL; Pyrroles	2007
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. The American journal of geriatric pharmacotherapy, 2007, Volume: 5, Issue:3 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2007
The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease. Cardiovascular ultrasound, 2007, Dec-30, Volume: 5 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Angiography; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Ultrasonography	2007
Analyzing the results of the treating to new targets study. Annals of internal medicine, 2008, Feb-19, Volume: 148, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Mortality; Pyrroles	2008
Analyzing the results of the treating to new targets study. Annals of internal medicine, 2008, Feb-19, Volume: 148, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Research Design	2008
Analyzing the results of the treating to new targets study. Annals of internal medicine, 2008, Feb-19, Volume: 148, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Neoplasms; Pyrroles	2008
Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease. Prilozi, 2007, Volume: 28, Issue:2 Topics: Adult; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles	2007
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:2 Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides	2008
[Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:16 Topics: Atorvastatin; Clopidogrel; Coronary Disease; Coronary Stenosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Stents; Ticlopidine	2008
Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Current medical research and opinion, 2008, Volume: 24, Issue:6 Topics: Atorvastatin; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Finland; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Markov Chains; Middle Aged; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
[Changes of blood lipids in colorectal cancer patients with coronary heart disease and value of lipid-lowering therapy with statins]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Colorectal Neoplasms; Coronary Disease; Female; Heptanoic Acids; Humans; Lipoprotein(a); Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides	2008
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis, 1996, Jan-26, Volume: 119, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin	1996
The emergence of triglycerides as a significant independent risk factor in coronary artery disease. European heart journal, 1998, Volume: 19 Suppl M Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Triglycerides	1998
Cost-effectiveness of statins. The American journal of cardiology, 1998, Dec-01, Volume: 82, Issue:11 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin	1998
After I had a heart attack and two bypass operations, I was put on Lipitor to lower my cholesterol. My cholesterol was never high--about 170-180 mg/dL. But my HDL was always low and triglycerides were somewhat high. Now my total cholesterol is 124 and my Harvard heart letter : from Harvard Medical School, 1999, Volume: 9, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypertriglyceridemia; Pyrroles	1999
Antioxidant therapy for coronary artery disease: don't paint the walls without treating the termites! Archives of internal medicine, 1999, Jun-28, Volume: 159, Issue:12 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Lung Neoplasms; Oxidation-Reduction; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Treatment Outcome; Vitamin A; Vitamin E	1999
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. The New England journal of medicine, 1999, Dec-09, Volume: 341, Issue:24 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Recurrence	1999
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. The New England journal of medicine, 1999, Dec-09, Volume: 341, Issue:24 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Stents	1999
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. The New England journal of medicine, 1999, Dec-09, Volume: 341, Issue:24 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles	1999
Effect of statin therapy on restenosis after coronary stent implantation. The American journal of cardiology, 2000, Apr-15, Volume: 85, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease-Free Survival; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperplasia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Stents; Time Factors; Tunica Intima	2000
[Will heart catheters besides hospitalization also become superfluous?. Interview by Dr. med. Ulrike Wepner]. MMW Fortschritte der Medizin, 1999, Dec-09, Volume: 141, Issue:49-50 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Pyrroles; Treatment Outcome	1999
Atorvastatin versus revascularization treatment (AVERT): fact or fancy? American heart journal, 2000, Volume: 140, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Myocardial Revascularization; Patient Selection; Pyrroles; Sensitivity and Specificity; Treatment Outcome	2000
[Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)]. Schweizerische medizinische Wochenschrift, 2000, Jun-10, Volume: 130, Issue:23 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Switzerland; Treatment Outcome	2000
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. The American journal of cardiology, 2000, Jul-15, Volume: 86, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic	2000
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. The American journal of cardiology, 2000, Nov-15, Volume: 86, Issue:10 Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome	2000
Status report of lipid-lowering trials in diabetes. Current opinion in lipidology, 2000, Volume: 11, Issue:6 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Risk Factors	2000
The state of the heart. If you thought cholesterol was all you had to worry about, better think again. Time, 2000, Nov-27, Volume: 156, Issue:22 Topics: American Heart Association; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Folic Acid; Heptanoic Acids; Humans; Inflammation; Pyrroles; United States	2000
Effect of atorvastatin 15 mg/week on serum lipids in patients with hypercholesterolemia. The American journal of cardiology, 2001, Feb-01, Volume: 87, Issue:3 Topics: Aged; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles	2001
[Disturbances in cholesterol metabolism]. Deutsche medizinische Wochenschrift (1946), 2001, Jan-19, Volume: 126, Issue:3 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Triglycerides	2001
Statins early in acute coronary syndromes. International journal of clinical practice, 2000, Volume: 54, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Treatment Outcome	2000
Cost effectiveness of HMG-CoA reductase inhibition in Canada. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2001,Spring, Volume: 8, Issue:1 Topics: Aged; Atorvastatin; Canada; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sensitivity and Specificity	2001
[Decreasing blood lipids for prevention of coronary heart disease--discussion of the "permissive LDL level". Diagnostic imaging facilitates therapeutic decision]. MMW Fortschritte der Medizin, 2001, Mar-29, Volume: 143, Issue:13 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diagnostic Imaging; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Treatment Outcome	2001
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels. International journal of clinical practice, 2001, Volume: 55, Issue:4 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin	2001
Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. European heart journal, 2001, Volume: 22, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Myocardial Revascularization; Pyrroles	2001
Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis, 2001, Volume: 157, Issue:2 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Coronary Disease; Exercise Test; Female; Heart Rate; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Time Factors	2001
Atorvastatin for acute coronary syndromes. JAMA, 2001, Aug-01, Volume: 286, Issue:5 Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles	2001
Atorvastatin for acute coronary syndromes. JAMA, 2001, Aug-01, Volume: 286, Issue:5 Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles	2001
Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. Controlled clinical trials, 2001, Volume: 22, Issue:5 Topics: Aged; Antioxidants; Atorvastatin; Calcinosis; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Pyrroles; Randomized Controlled Trials as Topic; Research Design	2001
Effects of atorvastatin (and blood pressure lowering comparing amlodipide-based therapy with beta-blocker-based therapy) on serum variables of cholesterol synthesis and absorption, thrombogenicity and on low-density lipoprotein oxidation in vivo. Journal of human hypertension, 2001, Volume: 15 Suppl 1 Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Oxidation-Reduction; Pyrroles; Sympatholytics; Thrombosis; Triglycerides	2001
Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines. Circulation, 2001, Nov-27, Volume: 104, Issue:22 Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States	2001
[60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high]. MMW Fortschritte der Medizin, 2001, Nov-01, Volume: 143, Issue:44 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors	2001
Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study. The Israel Medical Association journal : IMAJ, 2002, Volume: 4, Issue:6 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Israel; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome	2002
Routine statin treatment after acute coronary syndromes? American heart journal, 2002, Volume: 143, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Patient Discharge; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Thrombolytic Therapy; Treatment Outcome	2002
Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. Journal of the American College of Cardiology, 2002, Jun-19, Volume: 39, Issue:12 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Endothelial Growth Factors; Heptanoic Acids; Humans; Lymphokines; Male; Middle Aged; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002